FDA Approves Mobius Therapeutics’ Glaucoma Drug

The FDA has approved St. Louis-based Mobius Therapeutics’ Mitosol product for use in glaucoma surgery, according to a news release.

Advertisement

Mitosol is a system for delivering antifibrotic agents in glaucoma, refractive and corneal surgery, though the refractive and corneal indications are awaiting approval by the FDA.

Related Articles on Ophthalmology:
Pioneering Ophthalmologist Dr. Robert C. Welsh Dies at Age 89
Dr. Alan Faulkner Now Offering LenSx Femtosecond Laser at his Hawaii Cataract Surgery Practice
Dr. Ruth D. Williams Begins Term as President of the American Academy of Ophthalmology

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Uncategorized

Advertisement

Comments are closed.